Condition
Tumor Progression
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed2
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05553990Unknown
Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of AIS With Active Cancer
NCT04370860Completed
Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants
NCT04018183CompletedPrimary
The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer
NCT01959438Phase 1Unknown
Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma
Showing all 4 trials